Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Completed 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Gynecologic 1

Conditions

Multiple Myeloma 9Desmoid Tumors 4Triple Negative Breast Neoplasms 1Pancreatic Neoplasms 1Ovarian Neoplasms 1Neoplasms by Histologic Type 1Leukemia 1Granulosa cell tumor of the ovary 1Breast Cancer Metastatic 1Advanced Solid Tumors 1

Interventions

Paclitaxel 113Carboplatin 99Bevacizumab 59pembrolizumab 56liposomal doxorubicin 56Gemcitabine 42olaparib 39Topotecan 33niraparib 29Nivolumab 21Cisplatin 21Doxorubicin 17Cyclophosphamide 171-dodecylpyridoxal 16Drug Therapy 15Docetaxel 15avelumab 13Fulvestrant 11oregovomab 10Oxaliplatin 10rucaparib 9fludarabine 9Injections 9Fluorouracil 9veliparib 8mirvetuximab soravtansine 8atezolizumab 8Cetuximab 8fluzoparib 7cemiplimab 7

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
INDUSTRY × Ovarian Neoplasms × nirogacestat × Clear all
NCT05348356 2025-12-15

Nirogacestat in Ovarian Granulosa Cell Tumors

SpringWorks Therapeutics, Inc.

Phase 2 Completed
53 enrolled
Gynecologic

Granulosa cell tumor of the ovary, Ovarian Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡